Who is sponsoring NCT03840317?

NCT03840317 is sponsored by Hebei Senlang Biotechnology Inc., Ltd..

What drugs are being tested in NCT03840317?

Interventions in NCT03840317: Autologous CD19-targeting CAR T cells.

What condition does NCT03840317 study?

NCT03840317 studies Acute Lymphocytic Leukemia.

Is NCT03840317 still recruiting?

NCT03840317 is currently status unknown. Last updated 20 January 2021.

Last reviewed 2021-01-20 · How we verify

NCT03840317

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Senl_1904A and Senl_1904B Chimeric Antigen Receptor （CAR） T-Cell in the Treatment of r/ r Acute B Lymphocytic Leukemia

Status unknown Phase 1 Last updated 20 January 2021

What this trial tests

Phase 1 trial testing Autologous CD19-targeting CAR T cells in Acute Lymphocytic Leukemia in 20 participants. Status unknown.

Timeline

2 January 2019

Primary endpoint
1 September 2021

31 January 2022

Quick facts

Lead sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	20
Start date	2 January 2019
Primary completion	1 September 2021
Estimated completion	31 January 2022
Sites	1 location across China

Drugs / interventions tested

Autologous CD19-targeting CAR T cells — full drug profile →

Conditions studied

Acute Lymphocytic Leukemia — all drugs for Acute Lymphocytic Leukemia →

Sponsor

Hebei Senlang Biotechnology Inc., Ltd. — full company profile →

Who can join

Adults 3 to 65, any sex, with Acute Lymphocytic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open, two arms, mask phase I clinical study to evaluate efficacy and safety of two different chimeric antigen receptor T cell immunotherapies (Senl\_1904A and Senl\_1904B) targeting cluster of differentiation antigen 19 （CD19） in the treatment of Acute lymphocytic Leukemia. A total of 20 patients are planned to be enrolled following up half a year.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells <i>in vivo</i>.
Ho JY, Wang L, Liu Y, Ba M, et al · · 2021 · cited 44× · PMID 33869653 · DOI 10.1016/j.omtm.2021.03.007
The future of cellular immunotherapy for childhood leukemia.
Bonifant CL, Tasian SK. · · 2020 · cited 15× · PMID 31851053 · DOI 10.1097/mop.0000000000000866

Verify or expand the search:

Other recruiting trials for Acute Lymphocytic Leukemia

Currently open trials in the same condition.

NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
NCT07008885 — BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL · Phase 1, PHASE2 · recruiting
NCT06481735 — TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL · Phase 1, PHASE2 · recruiting
NCT06476665 — A Study to Learn About the Safety of BESPONSA Injection in Pediatric Patients With Acute Lymphocytic Leukemia. · active not recruiting
NCT06783816 — A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors · NA · recruiting

Other Hebei Senlang Biotechnology Inc., Ltd. trials

Trials by the same sponsor.

NCT07435779 — Autologous CAR-T Cell Therapy for Refractory and Relapsing Ulcerative Colitis: A Single-Center Exploratory Study · EARLY_PHASE1 · recruiting
NCT07421856 — Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. · Phase 1, PHASE2 · not yet recruiting
NCT07244380 — Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. · Phase 2 · not yet recruiting
NCT07161193 — Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases · Phase 1, PHASE2 · not yet recruiting
NCT07244406 — Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03840317 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hebei Senlang Biotechnology Inc., Ltd.
Last refreshed: 20 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03840317.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing